Clinical Scorecard: Cogninet: An Interpretable Deep Learning Approach for Staging Alzheimer's Disease Using Multi-Class MRI Data
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Individuals with cognitive impairment, including those with Mild Cognitive Impairment (MCI) and Progressive MCI (pMCI), particularly those transitioning to Alzheimer's Disease (AD).
Care Setting
Key Highlights
Cogninet enables four-way classification: Cognitively Normal (CN), Mild Cognitive Impairment (MCI), Progressive MCI (pMCI), and Alzheimer's Disease (AD).
Incorporates Grad-CAM for interpretability, enhancing clinician trust in AI diagnostics.
Outperforms baseline models in diagnostic accuracy, sensitivity, and precision.
Highlights the importance of explainability in AI for clinical trust.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Regularly assess cognitive stages using advanced imaging techniques and AI tools, such as specific algorithms or software.
Risks
Patient & Prescribing Data
Early identification of pMCI can facilitate timely and targeted interventions, such as cognitive therapies or lifestyle modifications.
Clinical Best Practices
Incorporate explainable AI tools, such as LIME or SHAP, in clinical workflows to enhance decision-making.
Ensure comprehensive MRI data preprocessing to improve diagnostic accuracy.
